Unicycive Therapeutics Inc. has released a corporate presentation detailing its focus on novel treatments for kidney disease. The presentation highlights the company's diversified portfolio, including lead asset OLC for hyperphosphatemia in chronic kidney disease patients on dialysis, and the development of UN-494 for acute kidney injury. Unicycive emphasizes its strong IP protection, experienced management team, and a cash runway extending into the second half of 2026. The company is working towards resubmitting its NDA for OLC, following a Complete Response Letter from the FDA addressing manufacturing vendor deficiencies. Additionally, recent developments in the reimbursement landscape have expanded the market opportunity for OLC. Unicycive also mentions its preparedness for the potential launch of OLC, contingent on future approval. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.